JP2008174457A - 2-(2-METHYLPROPANOYL)PHLOROGLUCINOL-1,5-DI-O-beta-D-GLUCOPYRANOSIDE HAVING ANTIOXIDANT ACTION - Google Patents

2-(2-METHYLPROPANOYL)PHLOROGLUCINOL-1,5-DI-O-beta-D-GLUCOPYRANOSIDE HAVING ANTIOXIDANT ACTION Download PDF

Info

Publication number
JP2008174457A
JP2008174457A JP2007007029A JP2007007029A JP2008174457A JP 2008174457 A JP2008174457 A JP 2008174457A JP 2007007029 A JP2007007029 A JP 2007007029A JP 2007007029 A JP2007007029 A JP 2007007029A JP 2008174457 A JP2008174457 A JP 2008174457A
Authority
JP
Japan
Prior art keywords
phloroglucinol
methylpropanoyl
glucopyranoside
compound
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007007029A
Other languages
Japanese (ja)
Other versions
JP5122147B2 (en
Inventor
Daiki Honma
大樹 本間
Motoyuki Tagashira
素行 田頭
Tomomasa Kanda
智正 神田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Breweries Ltd
Original Assignee
Asahi Breweries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Breweries Ltd filed Critical Asahi Breweries Ltd
Priority to JP2007007029A priority Critical patent/JP5122147B2/en
Publication of JP2008174457A publication Critical patent/JP2008174457A/en
Application granted granted Critical
Publication of JP5122147B2 publication Critical patent/JP5122147B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Non-Alcoholic Beverages (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new compound having an antioxidant action and usable as medicines, cosmetics, foods, drinks and degradation prevention agents effective for the prevention and treatment of various diseases hindering the health maintenance such as adult diseases and malignant rheumatoid arthritis and cosmetic troubles e.g. lesion such as scald, acne, and pigmented spot. <P>SOLUTION: The compound is 2-(2-methylpropanoyl)phloroglucinol-1,5-di-O-β-D-glucopyranoside expressed by chemical formula [1] or its pharmacologically allowable salt. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は、抗酸化作用を有し、成人病、悪性関節リウマチなど、健康維持上障害となる諸疾患、火傷などの外傷、にきび、しみなどの美容上の障害の予防、治療に効果を医薬品、化粧品、飲食品となり、劣化防止剤となる抗酸化作用を有する新規な2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドを提供する。   The present invention has an anti-oxidant effect and is effective in preventing and treating various diseases that are impaired in health maintenance such as adult diseases and malignant rheumatoid arthritis, trauma such as burns, acne and stains, and other cosmetic disorders. The present invention provides novel 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having an antioxidant action as a cosmetic and food / beverage product and serving as a deterioration inhibitor.

活性酸素や不飽和脂質から生成する過酸化脂質が、老化や成人病、難病の発症といった生体への悪影響を及ぼすことが近年明らかとなっており、活性酸素消去作用や過酸化脂質の生成抑制作用を有する、いわゆる抗酸化物質の探索や、動脈硬化症、高脂血症、それらにより発症する脳梗塞、悪性リウマチ、ベーチェット病、クローン病、潰瘍性大腸炎、肝炎、胃炎、パーキンソン病などの難病、農薬などの化学物質により惹起される疾患、光線過敏症、放射線障害等に対する治療薬としてのそれらの応用が一部で試みられている。また、活性酸素や過酸化脂質はしみ、そばかす、にきび、皮膚潰瘍などの成員にもなる他、食品を劣化させ嗜好的品質や栄養の低下を引き起こすことも知られてきているが、いまだにこれらの問題を十分に解決しうる物質が見出されていないのが現状である。   In recent years, it has been clarified that lipid peroxides generated from active oxygen and unsaturated lipids have adverse effects on the body such as aging, adult diseases, and intractable diseases. For so-called antioxidants, and atherosclerosis, hyperlipidemia, cerebral infarction caused by them, malignant rheumatism, Behcet's disease, Crohn's disease, ulcerative colitis, hepatitis, gastritis, Parkinson's disease, etc. Some of their applications as therapeutic agents for diseases caused by chemical substances such as agricultural chemicals, photosensitivity, and radiation damage have been attempted. In addition to being a member of active oxygen and lipid peroxide stains, freckles, acne, skin ulcers, etc., it has also been known to degrade food and cause a decline in taste quality and nutrition, but these are still The present condition is that the substance which can fully solve a problem is not found.

抗酸化化合物としては、例えば、ビタミンC(アスコルビン酸)などの水溶性抗酸化化合物、ビタミンE(α−トコフェノール)などの脂溶性抗酸化化合物、BHA(3−tert−ブチル−4−ヒドロキシアニソール)などの合成化合物が知られている。しかし、合成化合物BHAは発ガン性が報告されており、安全性の面から考えると原料として食品素材からの成分を摂取するほうが望ましい。有用な抗酸化剤が発明された場合、それは医薬品、化粧品、健康食品、食品添加物などとして利用価値のあるものである。   Examples of antioxidant compounds include water-soluble antioxidant compounds such as vitamin C (ascorbic acid), fat-soluble antioxidant compounds such as vitamin E (α-tocophenol), and BHA (3-tert-butyl-4-hydroxyanisole). Synthetic compounds such as) are known. However, since the synthetic compound BHA has been reported to be carcinogenic, it is desirable to ingest ingredients from food materials as raw materials from the viewpoint of safety. When a useful antioxidant is invented, it has utility value as a pharmaceutical, cosmetic, health food, food additive and the like.

本発明者らは、天然物由来で抗酸化作用を有する化合物を探索し、ホップを由来とする新規な2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドが優れた抗酸化作用を有することを見出し、本発明を完成するに至った。   The present inventors searched for a compound derived from a natural product and having an antioxidant action, and developed a novel 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-derived from hops. It has been found that D-glucopyranoside has an excellent antioxidant action, and the present invention has been completed.

なお、特許文献1、非特許文献1〜3に各種のフロロアシルフェノン配糖体が開示されているが、本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドとは構造を異にするものである。
WO 2006/093202号パンフレット J. Nat. Prod. 2005, 68, 1545-1548 Chinese Chemical Letters Vol. 15, No. 3, pp313-315, 2004 Planta Med 2004: 70: 1128-1134
Although various fluoroacylphenone glycosides are disclosed in Patent Document 1 and Non-Patent Documents 1 to 3, 2- (2-methylpropanoyl) phloroglucinol-1,5-di- of the present invention is disclosed. O-β-D-glucopyranoside has a different structure.
WO 2006/093202 pamphlet J. Nat. Prod. 2005, 68, 1545-1548 Chinese Chemical Letters Vol. 15, No. 3, pp313-315, 2004 Planta Med 2004: 70: 1128-1134

本発明は、以下に係わるものである。
(1) 化学式[1]
The present invention relates to the following.
(1) Chemical formula [1]

Figure 2008174457
Figure 2008174457

で表されることを特徴とする2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド又は薬学的に許容されるその塩。
(2) アサ科カラハナソウ属の植物から得られることを特徴とする(1)記載の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド。
(3) アサ科カラハナソウ属の植物がホップ(Humulus lupulus)である(2)記載の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド。
(4) (1)記載の化合物を有効成分とする抗酸化剤。
(5) (1)記載の化合物を有効成分とする医薬品。
(6) (1)記載の化合物を有効成分とする化粧品。
(7) (1)記載の化合物を有効成分とする飲食品。
2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof, wherein
(2) The 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside according to (1), which is obtained from a plant belonging to the genus Asperaceae.
(3) 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside according to (2), wherein the plant belonging to the genus Asperaceae is a hop (Humulus lupulus).
(4) An antioxidant comprising the compound according to (1) as an active ingredient.
(5) A pharmaceutical comprising the compound according to (1) as an active ingredient.
(6) A cosmetic comprising the compound according to (1) as an active ingredient.
(7) A food or drink comprising the compound according to (1) as an active ingredient.

本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド又は薬学的に許容されるその塩を含有する医薬品、化粧品、飲食品は、抗酸化作用を有するので、生体内に生成した活性酸素や過酸化脂質によって引き起こされる障害を抑制する効果を有する。従って、健康上の障害、美容上の障害の予防、治療に有効であり、また飲食品の安定化、保存性の向上に有用である。産業的に価値のあるものである。   The pharmaceuticals, cosmetics, foods and drinks containing 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside or pharmaceutically acceptable salts thereof of the present invention are Since it has an oxidizing action, it has the effect of suppressing damage caused by active oxygen and lipid peroxide generated in the living body. Therefore, it is effective for the prevention and treatment of health disorders and cosmetic disorders, and it is useful for stabilizing foods and beverages and improving storage stability. It is industrially valuable.

本発明者らは、ホップ(Humulus lupulus)より、前記一般式[1]で表される新規な2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドを単離し、それに強い抗酸化活性を有することを見出し、本発明を完成した。   The present inventors obtained a novel 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D- represented by the above general formula [1] from hop (Humulus lupulus). Glucopyranoside was isolated and found to have strong antioxidant activity, thereby completing the present invention.

ホップ(Humulus lupulus)から2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドを単離する方法としては、例えばWO2004/052898号パンフレットに記載された公知方法により抽出すればよい。   As a method for isolating 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside from hop (Humulus lupulus), for example, it was described in WO 2004/052898 pamphlet. What is necessary is just to extract by a well-known method.

本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドを医薬品、飲食品、化粧品として用いる場合、有利の形で用いることができるほか、薬学的に許容される塩の形で使用することもできる。   When 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside of the present invention is used as a pharmaceutical, food, drink or cosmetic, it can be used in an advantageous form, It can also be used in the form of a pharmaceutically acceptable salt.

薬学的に許容される塩としては、例えばナトリウム塩、カリウム塩、リチウム塩等のようなアルカリ金属塩、カルシウム塩、マグネシウム塩等のようなアルカリ土類金属塩、鉄塩、銅塩のような遷移金属塩、アンモニウム塩、エチルアミン類、トリエチルアミン類、ジエタノールアミン塩、トリエタノールアミン塩、ジシクロヘキシルアミン塩、ジメチルアミノエタノール、アルギニン塩またはエチレンジアミン塩等のようなアミン塩が挙げられる。   Examples of the pharmaceutically acceptable salt include alkali metal salts such as sodium salt, potassium salt and lithium salt, alkaline earth metal salts such as calcium salt and magnesium salt, iron salt and copper salt. Examples include transition metal salts, ammonium salts, ethylamines, triethylamines, diethanolamine salts, triethanolamine salts, dicyclohexylamine salts, dimethylaminoethanol, arginine salts, ethylenediamine salts, and the like.

これらの塩は、通常の手段で生成させることができ、例えば、塩が不溶な溶媒または溶質中で、あるいは真空乾燥又は凍結乾燥によって除去できる水のような溶媒中で、有利のフェノール酸の形にある本発明の化合物を1等量またはそれ以上の適当な塩基と反応させるか、適当なイオン交換樹脂にて、現存の塩のイオンを他のイオンに交換することにより生成させることができる。   These salts can be produced by conventional means, for example in the form of the advantageous phenolic acid in a solvent or solute in which the salt is insoluble or in a solvent such as water that can be removed by vacuum drying or freeze drying. The compound of the present invention can be produced by reacting the compound of the present invention with one equivalent or more of a suitable base, or by exchanging existing salt ions with other ions using a suitable ion exchange resin.

または、本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド又はその薬学的に許容される塩は一般に使用される担体、助剤、添加剤等とともに製剤化することができ、定法に従って経口、非経口の製品として、医薬品、医薬部外品、化粧品等の分野で利用することができる。または食品素材として、混合して飲食品とすることができる。   Alternatively, 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof of the present invention is a commonly used carrier, auxiliary agent, It can be formulated together with additives and the like, and can be used in the fields of pharmaceuticals, quasi-drugs, cosmetics and the like as oral and parenteral products according to a standard method. Or as a food material, it can mix and can be made into food-drinks.

医薬品は経口剤として錠剤、カプセル剤、顆粒剤、シロップ剤等が、非経口剤として軟膏剤、クリーム、水剤等の外用剤、無菌溶液剤や懸濁剤等の注射剤等がある。これらの製品を医薬として疾患に投与するときは、2mg〜500mgを1日に1ないし数回、すなわち2mg〜1000mgの全日量で投与し、十分にその効果を奏し得るものである。   Pharmaceutical products include tablets, capsules, granules, syrups and the like as oral preparations, and external preparations such as ointments, creams and liquids as parenteral preparations, and injections such as sterile solutions and suspensions. When these products are administered to a disease as a medicine, 2 mg to 500 mg can be administered once to several times a day, that is, a total daily dose of 2 mg to 1000 mg, and the effect can be sufficiently exerted.

本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドまたはその薬学的に許容される塩は、生理学的に認められるベヒクル、担体、賦形剤、結合剤、安定剤、香味剤等とともに要求される単位容量をとり得る。錠剤、カプセル剤に混和される佐薬は次のようなものである。トラガントゴム、アラビアゴム、コンスターチ、ゼラチンのような結合剤、微晶性セルロースのような賦形剤、コンスターチ、前ゼラチン化澱粉、アルギン酸のような膨化剤、ステアリン酸マグネシウムのような滑沢剤、ショ糖、乳糖、サッカリンのような甘味剤、ペパーミント、アカモノ油、チェリーのような香味剤など。また、カプセル剤の混合は上記の材料に更に油脂のような液体担体を含有することができ、また、他の材料は被覆剤として、又は製剤の物理的形態を別な方法で変化させるために存在させることができる。例えば、錠剤はシェラック、砂糖で被覆することができる。シロップ又はエリキシルは活性化合物、甘味剤としてショ糖、防腐剤としてメチル又はプロピルパラベン、色素およびチェリー又はオレンジ香味のような香味剤を含有することができる。   2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof of the present invention is a physiologically recognized vehicle, carrier, The required unit volume can be taken together with the form, binder, stabilizer, flavoring agent and the like. The adjuncts mixed in tablets and capsules are as follows. Binders such as tragacanth gum, gum arabic, starch, gelatin, excipients such as microcrystalline cellulose, starch, pregelatinized starch, swelling agents such as alginic acid, lubricants such as magnesium stearate, Sweeteners such as sugar, lactose, saccharin, flavoring agents such as peppermint, red mono oil, and cherry. In addition, the mixture of capsules can contain a liquid carrier such as fats and oils in addition to the above materials, and other materials can be used as coating agents or to change the physical form of the formulation in other ways. Can exist. For example, tablets can be coated with shellac, sugar. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl or propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.

注射剤のための無菌組成物は、注射用水のようなベヒクル中の活性物質、ごま油、ヤシ油、落花生油、綿実油のような天然産出植物油、またはエチルオレートのような合成脂肪ベヒクルを溶解または懸濁させる通常の方法によって処方することができる。または、緩衝材、防腐剤、酸化防止剤等を必要により配合することができる。   Sterile compositions for injections dissolve or suspend active substances in vehicles such as water for injection, naturally occurring vegetable oils such as sesame oil, coconut oil, peanut oil, cottonseed oil, or synthetic fat vehicles such as ethyl oleate. It can be formulated by the usual method of turbidity. Alternatively, a buffer material, an antiseptic, an antioxidant and the like can be blended as necessary.

外用剤としては基剤として、ワセリン、パラフィン、油脂類、ラノリン、マクロゴール等を用い、通常の方法によって、軟膏剤、クリーム剤等とする。   As an external preparation, petrolatum, paraffin, oils and fats, lanolin, macrogol and the like are used as a base, and an ointment, a cream and the like are obtained by a usual method.

本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド又は薬学的に許容されるその塩を添加した飲食品は、上記製剤の形態でもよいが、あめ、せんべい、クッキー、ジュースなどの形態でそれぞれの食品原料に所用量を加えて、一般の製造法により加工製造する。健康食品、機能性食品としての摂取は、病気予防、健康維持に用いられるので、経口摂取として1日数回に分けて、全日量として5mg〜500mgを含む加工品として摂取される。   The food and drink to which 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside of the present invention or a pharmaceutically acceptable salt thereof is added may be in the form of the above preparation. Although it is good, it is processed and manufactured by a general manufacturing method by adding a predetermined amount to each food ingredient in the form of candy, rice cracker, cookie, juice or the like. Ingestion as a health food or functional food is used for disease prevention and health maintenance, so it is taken as a processed product containing 5 mg to 500 mg as a total daily dose, divided into several times a day for oral intake.

また本発明の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドは、ビタミンC、ビタミンE、補酵素Qnなどの抗酸化活性を有する化合物と併用することができる。また、これらの物質は、本飲食品の安定化剤としても作用を有し、併用することが有用である。これの抗酸化物質は常用量以下で添加される。
実施例
以下実施例により本発明をさらに具体的に説明するが、本発明の範囲はこれらに限定されるものではない。
Further, 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside of the present invention includes compounds having antioxidant activity such as vitamin C, vitamin E, and coenzyme Qn. Can be used together. Moreover, these substances have an effect | action also as a stabilizer of this food-drinks, and it is useful to use together. These antioxidants are added below the normal dose.
EXAMPLES The present invention will be described more specifically with reference to the following examples. However, the scope of the present invention is not limited to these examples.

2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドの精製
ホップ(Humulus lupulus)から得られる苞(以下、ホップ苞という)より既知の文献(WO2004/052898号パンフレット)の方法に従い、ホップ苞ポリフェノール画分を調製した。すなわち、得られたホップ苞を50%エタノールで50℃、10時間の条件で抽出し、遠心分離で沈殿を除去し、上清を減圧濃縮した。得られた抽出物を水に再溶解し、合成樹脂SEPABEADS SP850 (三菱化学株式会社)を詰めたカラムに供し、水洗後、50%エタノールで溶出した。この画分をスプレードライし、得られた茶色の粉末をホップ苞ポリフェノール画分とした。ホップ苞ポリフェノール画分150gを蒸留水350mlに溶解し、ヘキサン350mlで3回、続いて残った水層をジエチルエーテル350mlで3回それぞれ溶媒分画した。次いで水画分を減圧、凍結乾燥することにより粉末化した。得られた粉末をSEPABEADS SP850樹脂カラム(三菱化学株式会社)にアプライし、水、25%エタノール、50%エタノールで段階的に溶出した。25%エタノール画分を減圧濃縮、凍結乾燥した。残渣2.6gを下記の条件で高速液体クロマトグラフィー(HPLC)に供し、60分のピークを分取精製した。
HPLC条件
カラム:Inertsil ODS−3(φ20×250mm、GLsciences)
流速:10ml/min
移動相:A液 0.1%ギ酸水溶液、B液 アセトニトリル:0.1%ギ酸水溶液=1:1 0→70min:90%A→70%A
検出:UV280nm
2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside purified hop (Humulus lupulus) obtained from cocoon (hereinafter referred to as hop cocoon) known literature (WO2004) / 052898 pamphlet), a hop koji polyphenol fraction was prepared. That is, the obtained hop koji was extracted with 50% ethanol at 50 ° C. for 10 hours, the precipitate was removed by centrifugation, and the supernatant was concentrated under reduced pressure. The obtained extract was redissolved in water, applied to a column packed with synthetic resin SEPABEADS SP850 (Mitsubishi Chemical Corporation), washed with water, and eluted with 50% ethanol. This fraction was spray-dried, and the resulting brown powder was used as the hop straw polyphenol fraction. 150 g of hop koji polyphenol fraction was dissolved in 350 ml of distilled water, and the solvent was fractionated three times with 350 ml of hexane, and then the remaining aqueous layer was three times with 350 ml of diethyl ether. Next, the water fraction was pulverized by lyophilization under reduced pressure. The obtained powder was applied to a SEPABEADS SP850 resin column (Mitsubishi Chemical Corporation) and eluted stepwise with water, 25% ethanol, and 50% ethanol. The 25% ethanol fraction was concentrated under reduced pressure and lyophilized. 2.6 g of the residue was subjected to high performance liquid chromatography (HPLC) under the following conditions, and a peak at 60 minutes was separated and purified.
HPLC condition column: Inertsil ODS-3 (φ20 × 250 mm, GLsciences)
Flow rate: 10 ml / min
Mobile phase: A solution 0.1% formic acid aqueous solution, B solution acetonitrile: 0.1% formic acid aqueous solution = 1: 10 → 70 min: 90% A → 70% A
Detection: UV280nm

凍結乾燥して2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド 9.28mgを淡黄色の粉末として得た。   Lyophilization gave 9.28 mg of 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside as a pale yellow powder.

2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシドの分子式と構造決定
精製した化合物の分子式をTOF−MS(飛行時間型質量分析)を用い、構造式をNMR(核磁気共鳴)を用いて決定した。
The molecular formula of 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside and the structure of the purified compound were determined using TOF-MS (time-of-flight mass spectrometry). The structural formula was determined using NMR (nuclear magnetic resonance).

TOF−MS測定
「UPLC/TOF−MS条件」
HPLC:ACQUITY UPLC(ウォーターズ)
カラム:ACQUITY UPLC BEH C18(50×2.1MM、1.7μm:ウォーターズ)
移動相:A液−メタノール B液−0.1(V/V)%ギ酸水溶液
10(V/V)A液(0min) → 50(V/V)A液(5min)
流速:0.6ml/min
カラム温度:40℃
注入量:5μl
検出器:LCT Premier(ウォーターズ)
イオン源:ESI(ポジティブ、ネガティブ)、
コーン電圧:30V
キャピラリー電圧:2500V
イオン源温度:120℃
デソルベーション温度:300℃
MSスキャン:m/z100−1000
ポジティブイオンモードの測定で、[M+H]=521、ネガティブイオンモードの測定で[M−H]=519のシグナルが観測されたことから、整数分子量を520と決定した。また、高分解能質量分析の結果より、分子式をC223214と決定した。
TOF-MS measurement "UPLC / TOF-MS conditions"
HPLC: ACQUITY UPLC (Waters)
Column: ACQUITY UPLC BEH C18 (50 × 2.1 MM, 1.7 μm: Waters)
Mobile phase: A liquid-methanol B liquid-0.1 (V / V)% formic acid aqueous solution
10 (V / V) A liquid (0 min) → 50 (V / V) A liquid (5 min)
Flow rate: 0.6 ml / min
Column temperature: 40 ° C
Injection volume: 5 μl
Detector: LCT Premier (Waters)
Ion source: ESI (positive, negative),
Cone voltage: 30V
Capillary voltage: 2500V
Ion source temperature: 120 ° C
Desolvation temperature: 300 ° C
MS scan: m / z 100-1000
The signal of [M + H] + = 521 was observed in the positive ion mode measurement, and the signal [M−H] = 519 was observed in the negative ion mode measurement. Therefore, the integer molecular weight was determined to be 520. Moreover, the molecular formula was determined as C 22 H 32 0 14 from the results of high-resolution mass spectrometry.

NMR測定
精製した化合物をCD3ODに溶解した。NMR測定にはXWIN−NMR AV600(Bruker Biospin)を用い、各種NMRスペクトル(1H,13C、HSQC、HMBC)を測定した。表1に測定結果を示した。その結果、化合物を2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド(以下、MPOGと略する場合がある)と決定した。
The compound purified by NMR measurement was dissolved in CD3OD. Various NMR spectra (1H, 13C, HSQC, HMBC) were measured using XWIN-NMR AV600 (Bruker Biospin) for NMR measurement. Table 1 shows the measurement results. As a result, the compound was determined to be 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside (hereinafter sometimes abbreviated as MPOG).

Figure 2008174457
Figure 2008174457

(抗酸化活性測定)
DPPHラジカル消去活性
(Measurement of antioxidant activity)
DPPH radical scavenging activity

Figure 2008174457
Figure 2008174457

既知のアシルフロログルシノール一配糖体2−(2−メチルプロパノイル)フロログルシノール−1−O−β−D−グルコピラノシド(化2)、新規化合物MPOGについて、DPPH(1,1−ジフェニル−2−ピクリルヒドラジル)ラジカル消去活性を測定した。すなわち、96ウエルプレート中でサンプルの希釈系列を作製し、1ウエル100μl)、750μM DPPH溶液(50%メタノール溶液)100μlを加え、室温で30分間放置した後に550nmでの吸光度を測定した。吸光度を半減させる供試物質の最終濃度(IC50)を求め、これを抗酸化活性の指標とした。その結果を図1に示した。MPOGは2−(2−メチルプロパノイル)フロログルシノール−1−O−β−D−グルコピラノシドよりも強い活性を示した。(IC50はそれぞれ0.10mM、1.01mM)。 For the known acylphloroglucinol monoglycoside 2- (2-methylpropanoyl) phloroglucinol-1-O-β-D-glucopyranoside (Chemical Formula 2), a new compound MPOG, DPPH (1,1-diphenyl- (2-picrylhydrazyl) radical scavenging activity was measured. Specifically, a dilution series of samples was prepared in a 96-well plate, 100 μl of 1 well was added, 100 μl of 750 μM DPPH solution (50% methanol solution) was added, and the mixture was allowed to stand at room temperature for 30 minutes, and then the absorbance at 550 nm was measured. The final concentration (IC 50 ) of the test substance that reduces the absorbance by half was determined and used as an index of antioxidant activity. The results are shown in FIG. MPOG showed stronger activity than 2- (2-methylpropanoyl) phloroglucinol-1-O-β-D-glucopyranoside. (IC 50 are 0.10 mM and 1.01 mM, respectively).

これらの結果から、抗酸化作用の高い新規なアシルフロログルシノール二糖配糖体を取得できたことが明らかとなった。   From these results, it was revealed that a novel acyl phloroglucinol disaccharide glycoside having a high antioxidant action could be obtained.

(錠剤、カプセル剤)
実施例1で得られた化合物(MPOG) 10%
乳糖 75%
ステアリン酸マグネシウム 15%
上記の成分を均一に混合し、錠剤およびカプセル剤とした。
(Tablets and capsules)
10% of the compound (MPOG) obtained in Example 1
Lactose 75%
Magnesium stearate 15%
The above ingredients were uniformly mixed to obtain tablets and capsules.

(散剤、顆粒剤)
実施例1で得られた化合物(MPOG) 20%
澱粉 30%
乳糖 50%
上記の成分を均一に混合し、散剤および顆粒剤とした。
(Powder, granule)
Compound obtained in Example 1 (MPOG) 20%
Starch 30%
Lactose 50%
The above ingredients were mixed uniformly to obtain a powder and granules.

(注射剤)
実施例1で得られた化合物(MPOG) 1%
界面活性剤 9%
生理食塩水 90%
上記の成分を加熱混合し、滅菌して注射剤とした。
(Injection)
Compound obtained in Example 1 (MPOG) 1%
Surfactant 9%
Saline 90%
The above ingredients were mixed by heating and sterilized to give an injection.

(クッキー)
実施例1で得られた化合物(MPOG)を2重量%を含む小麦粉に、食塩、ショ糖、バターなどで味付けしたものを適量の水でよく攪拌し、190〜200℃で30分間焼き上げてクッキーとした。
(cookie)
A wheat flour containing 2% by weight of the compound (MPOG) obtained in Example 1 and seasoned with salt, sucrose, butter, etc., is thoroughly stirred with an appropriate amount of water, baked at 190-200 ° C. for 30 minutes, and cookie. It was.

(ゼリー)
寒天13gを水1リットルに加熱溶解し、さらにショ糖500g、水飴150g及び塩少々を加え、攪拌しながら加熱溶解させた後、2重量%の実施例1で得られた化合物(MPOG)、果汁、着色料、香料などを加えて冷却し、ゼリーとした。
(jelly)
13 g of agar was dissolved by heating in 1 liter of water, 500 g of sucrose, 150 g of starch syrup and a little salt were added, and the mixture was heated and dissolved with stirring. Then, 2% by weight of the compound (MPOG) obtained in Example 1 and fruit juice Then, coloring and flavoring were added and cooled to make a jelly.

(あめ)
ショ糖20重量部、水飴(75%固形分)10量部に水10量部を加え混合し、150℃に加熱攪拌後、2重量%の実施例1で得られた化合物(MPOG)および着色料、香料などを加え、冷却してあめとした。
(Rain)
20 parts by weight of sucrose and 10 parts by weight of starch syrup (75% solids) were added and mixed with 10 parts of water. After heating and stirring at 150 ° C., 2% by weight of the compound (MPOG) obtained in Example 1 and coloring Add fragrance, fragrance, etc. and cool to make candy.

(ハンドローション剤)
カーボンワックス1500を15重量部、アルコール8重量部およびプロピレングリコール90重量部をよく混合溶解し、水52.5重量部、実施例1で得られた化合物(MPOG)2重量部および香料、防腐剤を適量加え、ハンドローション剤とした。
(Hand lotion)
15 parts by weight of carbon wax 1500, 8 parts by weight of alcohol and 90 parts by weight of propylene glycol were mixed and dissolved well, 52.5 parts by weight of water, 2 parts by weight of the compound (MPOG) obtained in Example 1, and a fragrance and preservative. An appropriate amount was added to obtain a hand lotion.

(外用剤)
パラオキシ安息香酸エチル0.1%、パラオキシ安息香酸ブチル0.1%、ラウロマクロゴール0.5%、セタノール18%、白色ワセリン40%、水37.3%、実施例1で得られた化合物(MPOG)4%を混合し、定法に従って軟膏とした。
(External preparation)
Ethyl paraoxybenzoate 0.1%, butyl paraoxybenzoate 0.1%, lauromacrogol 0.5%, cetanol 18%, white petrolatum 40%, water 37.3%, the compound obtained in Example 1 ( MPOG) 4% was mixed to make an ointment according to a conventional method.

本発明により、抗酸化作用を有したホップ由来新規化合物を提供することができる。抗酸化作用を有するので、生体内に生成した活性酸素や過酸化脂質によって引き起こされる障害を抑制する効果を有する。従って、健康上の障害、美容上の障害の予防、治療に有効であり、医薬品、飲食品、化粧品に応用、加工ができる。   According to the present invention, a new hop-derived compound having an antioxidant action can be provided. Since it has an antioxidant action, it has an effect of suppressing damage caused by active oxygen and lipid peroxide generated in the living body. Therefore, it is effective for the prevention and treatment of health disorders and cosmetic disorders, and can be applied and processed in medicines, foods and drinks, and cosmetics.

DDPHアッセイの結果を示すグラフ。The graph which shows the result of a DDPH assay.

Claims (7)

化学式[1]
Figure 2008174457
で表されることを特徴とする2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド又は薬学的に許容されるその塩。
Chemical formula [1]
Figure 2008174457
2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof, wherein
アサ科カラハナソウ属の植物から得られることを特徴とする請求項1記載の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド。 The 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside according to claim 1, which is obtained from a plant belonging to the genus Asperaceae. アサ科カラハナソウ属の植物がホップ(Humulus lupulus)である請求項2記載の2−(2−メチルプロパノイル)フロログルシノール−1,5−ジ−O−β−D−グルコピラノシド。 The 2- (2-methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside according to claim 2, wherein the plant of the genus Asaaceae is a hop (Humulus lupulus). 請求項1記載の化合物を有効成分とする抗酸化剤。 An antioxidant comprising the compound according to claim 1 as an active ingredient. 請求項1記載の化合物を有効成分とする医薬品。 A pharmaceutical comprising the compound according to claim 1 as an active ingredient. 請求項1記載の化合物を有効成分とする化粧品。 A cosmetic comprising the compound according to claim 1 as an active ingredient. 請求項1記載の化合物を有効成分とする飲食品。 A food or drink comprising the compound according to claim 1 as an active ingredient.
JP2007007029A 2007-01-16 2007-01-16 2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having antioxidant activity Expired - Fee Related JP5122147B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007007029A JP5122147B2 (en) 2007-01-16 2007-01-16 2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having antioxidant activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007007029A JP5122147B2 (en) 2007-01-16 2007-01-16 2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having antioxidant activity

Publications (2)

Publication Number Publication Date
JP2008174457A true JP2008174457A (en) 2008-07-31
JP5122147B2 JP5122147B2 (en) 2013-01-16

Family

ID=39701751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007007029A Expired - Fee Related JP5122147B2 (en) 2007-01-16 2007-01-16 2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having antioxidant activity

Country Status (1)

Country Link
JP (1) JP5122147B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009209060A (en) * 2008-03-03 2009-09-17 Hiroshima Univ New physiologically active composition
JP2010104364A (en) * 2009-09-18 2010-05-13 Uha Mikakuto Co Ltd Food and drink containing neurogenesis promoter
JP2012508214A (en) * 2008-11-10 2012-04-05 ギウリアニ ソシエタ ペル アチオニ Use of compounds to inhibit 5α-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing the same
JP5728105B1 (en) * 2014-03-04 2015-06-03 株式会社エヌ・ティー・エイチ New component of henna flower

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052898A1 (en) * 2002-12-12 2004-06-24 Asahi Breweries, Ltd. Process for producing hop glume polyphenol
JP2008069072A (en) * 2005-03-03 2008-03-27 Sapporo Breweries Ltd Phloroacylphenone glycoside, its manufacturing method, antiallergic agent and antioxidant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052898A1 (en) * 2002-12-12 2004-06-24 Asahi Breweries, Ltd. Process for producing hop glume polyphenol
JP2008069072A (en) * 2005-03-03 2008-03-27 Sapporo Breweries Ltd Phloroacylphenone glycoside, its manufacturing method, antiallergic agent and antioxidant

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009209060A (en) * 2008-03-03 2009-09-17 Hiroshima Univ New physiologically active composition
JP2012508214A (en) * 2008-11-10 2012-04-05 ギウリアニ ソシエタ ペル アチオニ Use of compounds to inhibit 5α-reductase enzyme activity, and pharmaceutical and cosmetic compositions containing the same
JP2010104364A (en) * 2009-09-18 2010-05-13 Uha Mikakuto Co Ltd Food and drink containing neurogenesis promoter
JP5728105B1 (en) * 2014-03-04 2015-06-03 株式会社エヌ・ティー・エイチ New component of henna flower
JP2015168613A (en) * 2014-03-04 2015-09-28 株式会社エヌ・ティー・エイチ New component of henna flower part

Also Published As

Publication number Publication date
JP5122147B2 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
KR20150057899A (en) Composition for skin cell regeneration, anti-wrinkle, anti-imflamation or skin whitening
JP5122147B2 (en) 2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having antioxidant activity
KR101630782B1 (en) Glucosinolate Compound from Broccoli and Composition Having Antioxidant and Antimicrobial Activity Comprising the Same
JP5122148B2 (en) 2-Acylphloroglucinol-4,6-di-C-β-D-glucopyranoside having antioxidant activity
KR102001043B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR101988909B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR101999698B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
WO2022254867A1 (en) Novel phenylpropanoid compound
KR101988907B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR102002544B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR101989012B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR101988910B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20150019679A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation
KR102001042B1 (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20150019578A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20150019632A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20150019677A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20150019634A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation
KR20190087371A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20190068502A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20190086642A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening
KR20150057767A (en) Cosmetic composition containing Oriental Herb Fragrance Active Component 8-heptadecene for Skin Benefit Ingredient
KR20150058706A (en) Cosmetic composition containing Oriental Herb Fragrance Active Component L-menthone for Skin Benefit Ingredient
KR20150057764A (en) Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient
KR20150019552A (en) Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121009

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121024

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151102

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5122147

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02